Skip to content

Author

Sachin S. Goel

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Case report Open access Oct 2026

3D Intracardiac Echocardiography-Guided Mitral M-TEER for a Challenging Medial P3 Flail in Patient With Esophagectomy.

BACKGROUND Transesophageal echocardiography (TEE) is the standard imaging modality for mitral transcatheter edge-to-edge repair (M-TEER). When TEE is contraindicated, 3-dimensional intracardiac echocardiography (ICE) may provide an alternative; however, published experience remains limited and has predominantly involve...

Karl Abou Zeid, Charishma S. Nallapati, C. Kharsa et al. · 0 citations
Open access Sep 2026

Pooled Analysis of Valve-in-Valve and Valve-in-Ring Transcatheter Mitral Valve Replacement Using the SAPIEN Valve.

BACKGROUND Transcatheter mitral valve replacement (TMVR) using the Sapien (Edwards Lifesciences, Irvine, CA) transcatheter heart valve has become the preferred treatment for high-risk patients with failed mitral bioprosthetic valves or prior surgical mitral valve repairs. Differences in anatomy and procedural complexit...

C. Kharsa, S. Samimi, A. Agrawal et al. · 0 citations
Sep 2026

Impact of Initial Valve Type on Reintervention for TAVR Failure: From the EXPLANTORREDO-TAVR International Registry.

BACKGROUND As transcatheter aortic valve replacement (TAVR) expands to younger patients, there is limited data on the impact of TAV type on outcomes of TAVR-explant and redo-TAVR for TAVR failure. We sought to compare outcomes of reintervention for failed balloon-expandable valves (BEV) versus self-expanding valves (SE...

Syed Zaid, Tsuyoshi Kaneko, O. de Backer et al. · 0 citations
Open access Aug 2026

Redo-Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis.

In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR and support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.

Toby Rogers, V. Bapat, S. Chetcuti et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.